The correlation between inflammatory state and different pathologies is wellknown, as well as the possibility of combining conventional therapies with the use of probiotic bacteria or functional ingredients that can modulate their impairing effect. AAT has developed a wide range of pre-clinical models aiming to induce or verify inflammatory damage by highlighting the effect of using probiotics in different pathologies, reducing the systemic inflammatory state that characterizes them. Our team is able to design inflammation mitigation tests on:

  • Gestational diabetes models;
  • Models of type 2 diabetes mellitus;
  • Models of obesity;
  • IBS models.